dr_yakupergun· @dr_yakupergun · X·· 3 天前评分60
正文 · 机器翻译
#ESMO26 | PERSEE——III期
在晚期 NSCLC 且 PD-L1 ≥50% 的患者中，在 pembrolizumab 基础上加用化疗，将中位 PFS 从 6.9 个月延长至 16.1 个月（HR 0.56）。OS 的数值差异引人注目（50.2 vs 29.9 个月；HR 0.77），但未达到统计学显著性。不过，我们应记住，OS 并非主要终点！
≥3 级毒性：53.8% vs 19.3%。
我认为，加用化疗能够带来获益，但代价是毒性增加。我们需要更好地识别哪些患者值得承受这种毒性。
热度 54 · 42 赞 · 0 回复 · 12 转发
会议摘要
NCT02504372NCT02504372按 - **标题 / Title：** Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) 对上
- **标题 / Title：** Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)读摘要原文 →NCT03425643NCT03425643按 - **标题 / Title：** Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) 对上
- **标题 / Title：** Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)读摘要原文 →NCT03924895NCT03924895按 - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) 对上
- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)读摘要原文 →NCT04210115NCT04210115按 - **标题 / Title：** Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) 对上
- **标题 / Title：** Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)读摘要原文 →NCT04547504NCT04547504按 - **标题 / Title：** PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % 对上
- **标题 / Title：** PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %读摘要原文 →NCT04700124NCT04700124按 - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 对上
- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)读摘要原文 →来源：dr_yakupergun · x.com